Sector
PharmaceuticalsOpen
₹6,500Prev. Close
₹6,493Turnover(Lac.)
₹36,976.63Day's High
₹6,602.5Day's Low
₹6,455.552 Week's High
₹6,862.552 Week's Low
₹4,395.3Book Value
₹591.15Face Value
₹2Mkt Cap (₹ Cr.)
1,74,996.89P/E
79.2EPS
83.21Divi. Yield
0.458 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
25 May 2024
12:00 AM
AGM
Announcement Date: 25 May, 2024
25 May 2024
12:00 AM
Dividend
Dividend Amount: 30
Record Date: 02 Aug, 2024
EBITDA increased 21.2% yoy to ₹886 crore led by EBITDA margin expansion to 25.6%.
In a regulatory filing to the stock exchanges, Divi’s stated that the partnership is global in scope and is expected to significantly contribute to the company’s revenue over the coming years.
EBITDA reached ₹716 crore for the quarter, marking a 49.5% rise compared to ₹479 crore in Q2 2023.
Here are some of the stocks that may see significant price movement today: Tata Motors, Asian Paints, Divi’s Laboratories, etc.
The company's first-quarter earnings before interest, taxes, depreciation, and amortisation (EBITDA) were ₹622 Crore.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 53 | 53 | 53.09 | 53.09 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 13,431 | 12,652 | 11,638.26 | 9,218.48 |
Net Worth | 13,484 | 12,705 | 11,691.35 | 9,271.57 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 8,879.82 | 6,798.61 | 5,310.57 | 3,815.94 |
yoy growth (%) | 30.61 | 28.02 | 39.16 | -5.16 |
Raw materials | -2,989.8 | -2,265.5 | -2,088.56 | -1,504.9 |
As % of sales | 33.66 | 33.32 | 39.32 | 39.43 |
Employee costs | -926.55 | -808.68 | -608.36 | -446.27 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 3,676.52 | 2,627.87 | 1,813.29 | 1,219.36 |
Depreciation | -310.55 | -254.65 | -185.95 | -142.42 |
Tax paid | -727.98 | -673.15 | -440.58 | -349.78 |
Working capital | 2,090.79 | 2,216.26 | 733.27 | 298.91 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 30.61 | 28.02 | 39.16 | -5.16 |
Op profit growth | 37.42 | 55.37 | 45.16 | -13.01 |
EBIT growth | 39.89 | 44.47 | 49.04 | -12.21 |
Net profit growth | 50.84 | 42.39 | 57.85 | -17.43 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 9,360 | 7,845 | 7,767 | 8,959.83 | 6,969.4 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 9,360 | 7,845 | 7,767 | 8,959.83 | 6,969.4 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 352 | 339 | 345 | 113.87 | 62.56 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.6 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,484 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.1 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,164 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Murali K Divi
Executive Director
N V Ramana
Whole Time Director & CEO
Kiran S Divi
Independent Director
K V K Seshavataram
Chairman & Independent Directo
Ramesh B V Nimmagadda
Whole Time Director -Commercia
Nilima Motaparti
Independent Director
S Ganapaty
Independent Director
Sunaina Singh
Independent Director
Kosaraju Veerayya Chowdary
Company Sec. & Compli. Officer
Satish Choudhury
Whole-time Director
S. Devendra Rao
Independent Director
Rajendrakumar Premchand Shah
1-72-23(P)/DIVIS/303 Divi Towe,
Cyber Hills Gachibowli,
Telangana - 500032
Tel: 91-40-23786300/23786352/400
Website: http://www.divislabs.com
Email: mail@divislaboratories.com; cs@divislaboratories.c
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@kfintech.com
Summary
Divis Laboratories Limited is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals. The Company is one of ...
Read More
Reports by Divis Laboratories Ltd
What is the Divis Laboratories Ltd share price today?
What is the Market Cap of Divis Laboratories Ltd?
What is the PE and PB ratio of Divis Laboratories Ltd?
What is the 52 Week High and Low of Divis Laboratories Ltd?
What is the CAGR of Divis Laboratories Ltd?
What is the shareholding pattern of Divis Laboratories Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
